
RealRate

PHARMACEUTICAL 2018

INTERCEPT PHARMACEUTICALS INC.



Rank 234 of 349



RealRate

PHARMACEUTICAL 2018

INTERCEPT PHARMACEUTICALS INC.



Rank 234 of 349

The relative strengths and weaknesses of INTERCEPT PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTERCEPT PHARMACEUTICALS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 61% points. The greatest weakness of INTERCEPT PHARMACEUTICALS INC. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is -303%, being 26% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	448,307
Cost of Goods Sold	1,371
Intangible Assets	0
Liabilities, Current	104,034
Liabilities, Non-Current	361,255
Other Assets	19,856
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	2,672
Other Net Income	-24,755
Property and Equipment	16,184
Research and Development	191,499
Revenues	130,956
Selling, General and Administrative Expense	273,698

Output Variable	Value in 1000 USD
Assets	484,347
Liabilities	467,961
Expenses	466,568
Stockholders Equity	16,386
Net Income	-360,367
Comprehensive Net Income	-360,367
Economic Capital Ratio	-303%